Published in Women's Health Weekly, February 24th, 2011
"We investigated the activity of 8 courses of PLD in combination with cisplatin and infusional 5-fluorouracil (CCF) plus 3-week trastuzumab in patients with primary or recurrent cT2-T4 a-d, N0-3, MO any estrogen receptor (ER), HER2-positive breast cancer. with ER and/or progesterone receptor (PgR) 10% tumors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly